Detail akcie Cellectis online

Business Summary: Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Financial Summary: BRIEF: For the six months ended 30 September 2023, Cellectis SA revenues decreased 9% to $5.2M. Net loss applicable to common stockholders excluding extraordinary items decreased 21% to $42.9M. Revenues reflect Therapeutics segment decrease of 37% to $3.6M, Plants segment decrease of 43% to $42K. Lower net loss reflects Therapeutics segment loss decrease of 59% to $23.4M, Plants segment loss decrease of 70% to $3.6M.